{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:23Z","timestamp":1787017043476,"version":"build-2736575974"},"reference-count":22,"publisher":"BMJ","issue":"3","funder":[{"name":"Health Education England"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2017,6,7]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Controlling seizures in children approaching death can be difficult, and there is a limited evidence base to guide best practice. We compared current practice against the guidance for seizure management produced by the Association of Paediatric Palliative Medicine (APPM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective case note review of episodes of challenging seizure management in children receiving end-of-life care over a 10-year period (2006\u20132015) in the south-west region of England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We reviewed 19 admissions, in 18 individuals. Six (33%) had a malignancy, nine (50%) had a progressive neurodegenerative condition and three (17%) had a static neurological condition with associated epilepsy. Thirteen (72%) died in their local hospice, four (22%) at home, and one (6%) in hospital. Seventeen of 19 episodes involved the use of subcutaneous or intravenous midazolam infusion, for a mean of 11 days (range 3\u201327). There was a wide range of starting doses of midazolam, and 9\/17 (53%) received final doses in excess of current dose recommendations. Six individuals received subcutaneous phenobarbital infusions, with four of these (67%) receiving final doses in excess of current dose recommendations. Plans for adjustments of infusion rates, maximal doses or alternative approaches should treatment fail were inconsistent or absent. In 16\/18 (88%) cases seizures were successfully controlled prior to the day of the child\u2019s death. Staff found the experience of managing seizures at end of life challenging and stressful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacological approaches to seizure management in end-of-life care are variable, often exceeding APPM dose recommendations. Despite this, safe and effective seizure control was possible in all settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjspcare-2017-001366","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T20:55:25Z","timestamp":1499460925000},"page":"e22-e22","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Seizure management in children requiring palliative care: a review of current practice"],"prefix":"10.1136","volume":"10","author":[{"given":"Nicola","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Beringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta","family":"Sharples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"key":"2024051613285608000_10.3.e22.1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216314528743"},{"key":"2024051613285608000_10.3.e22.2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25160"},{"key":"2024051613285608000_10.3.e22.3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/B978-0-444-53501-6.00011-1","article-title":"Care of the dying neurologic patient","volume":"118","author":"Voltz","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"2024051613285608000_10.3.e22.4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/082585970702300408","article-title":"Symptom prevalence among people affected by advanced and progressive neurological conditions-a systematic review","volume":"23","author":"Saleem","year":"2007","journal-title":"J Palliat Care"},{"key":"2024051613285608000_10.3.e22.5","doi-asserted-by":"publisher","DOI":"10.1177\/104990910201900409"},{"key":"2024051613285608000_10.3.e22.6","doi-asserted-by":"publisher","DOI":"10.1177\/0883073814527159"},{"key":"2024051613285608000_10.3.e22.7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01376517-200404000-00003","article-title":"Withholding aggressive seizure treatment from a child with severe intractable epilepsy: a case study","volume":"36","author":"Boyd","year":"2004","journal-title":"J Neurosci Nurs"},{"key":"2024051613285608000_10.3.e22.8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2214.1995.tb00767.x","article-title":"Subcutaneous midazolam, diamorphine and hyoscine infusion in palliative care of a child with neurodegenerative disease","volume":"21","author":"Grimshaw","year":"1995","journal-title":"Child Care Health Dev"},{"key":"2024051613285608000_10.3.e22.9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/15360280903583107","article-title":"Seizure management in a complex hospice patient","volume":"24","author":"Juba","year":"2010","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2024051613285608000_10.3.e22.10","doi-asserted-by":"publisher","DOI":"10.1097\/NJH.0b013e3182a57212"},{"key":"2024051613285608000_10.3.e22.11","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s00415-013-7067-z","article-title":"Perioperative substitution of anti-epileptic drugs","volume":"260","author":"Wichards","year":"2013","journal-title":"J Neurol"},{"key":"2024051613285608000_10.3.e22.12","doi-asserted-by":"crossref","unstructured":"Cheng C , Roemer-Becuwe C , Pereira J , et al . Pain and Symptom Management. 2002;23:256\u201365.","DOI":"10.1016\/S0885-3924(01)00412-2"},{"key":"2024051613285608000_10.3.e22.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.01.017"},{"key":"2024051613285608000_10.3.e22.14","doi-asserted-by":"crossref","unstructured":"Jassal S . Basic Symptom Control in Paediatric Palliative Care. Eighth Edition, 2011. . http:\/\/www.togetherforshortlives.org.uk\/professionals\/resources\/2434_basic_symptom_control_in_paediatric_palliative_care_free_download. (accessed 26 May 2015).","DOI":"10.1016\/j.paed.2015.10.004"},{"key":"2024051613285608000_10.3.e22.15","unstructured":"Neurological symptoms in Palliative Care. http:\/\/www.rch.org.au\/rch_palliative\/for_health_professionals\/Neurological_symptoms\/ (accessed 28 June \u00a02015)."},{"key":"2024051613285608000_10.3.e22.16","unstructured":"Association of Paediatric Palliative Medicine Master Formulary 2015.http:\/\/appm.org.uk\/resources\/APPM+Master++Formulary+2015+protected.pdf. accessed 2 Mar 2016."},{"key":"2024051613285608000_10.3.e22.17","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.160051"},{"key":"2024051613285608000_10.3.e22.18","unstructured":"Royal Pharmaceutical Society of Great Britain, and British Medical Association. British National Formulary for Children. 2014\/15 ed. London: BMJ Group, 2014."},{"key":"2024051613285608000_10.3.e22.19","unstructured":"Twycross R , Wilcock A , Howard P . Palliative Care Formulary. 5th ed. Nottingham UK: Palliativedrugs.com Ltd, 2014."},{"key":"2024051613285608000_10.3.e22.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.01.006"},{"key":"2024051613285608000_10.3.e22.21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/15360288.2014.959234","article-title":"Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects","volume":"28","author":"R\u00e9mi","year":"2014","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2024051613285608000_10.3.e22.22","unstructured":"NICE. End of Life Care for Infants. Children and Young People: Planning and Management, 2016. https:\/\/www.nice.org.uk\/guidance\/GID-CGWAVE0730\/documents\/draft-guideline. (accessed 29 July 2016)."}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjspcare-2017-001366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:32:43Z","timestamp":1715877163000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/bmjspcare-2017-001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/bmjspcare-2017-001366"],"URL":"https:\/\/doi.org\/10.1136\/bmjspcare-2017-001366","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,7]]}}}